Brand name · Tiotropium bromide
Spiriva Handihaler: adverse event reports filed with FDA
776 reports list it as a suspect or interacting product, 2004–2024.
- 776
- reports as suspect product
- 0% of all reports · about 36 a year
- 0
- reports, 12 months to June 2026
- 10 in the 12 months before
- 18.3%
- marked serious by the reporter
- 57.4% across all reports
- 3.1%
- record death among outcomes, as reported
- 24 reports · not verified by FDA
776 adverse event reports received by FDA list the brand name Spiriva Handihaler (tiotropium bromide) as a suspect or interacting product, from December 2004 to August 2024. A further 241 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, against 10 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 36 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are incorrect route of product administration (25.1%), product physical issue (14%) and dyspnoea (12.5%). A report can list several reactions, so shares add to more than 100%; 124 different terms appear across these reports. Incorrect route of product administration is recorded in 25.1% of these reports, against 0.1% of all reports in the database.
18.3% of the reports are marked serious by the reporter; 3.1% record death among the outcomes and 8.2% record hospitalisation, as reported. 91.2% of the reports came from consumers, and the largest patient age group is 75 and over (20.5%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Spiriva Handihaler reports recording the termall reports in the database
- Incorrect route of product administrationthe product was given by the wrong route25.1%195
- Product physical issuea physical defect in the product14%109
- Dyspnoeashortness of breath12.5%97
- Product use issuea problem in how the product was used12.2%95
- Product quality issuea problem with the product itself9.5%74
- Off label useused for a purpose or in a way not on the label9.1%71
- Extra dose administered8.6%67
- Intentional product use issuedeliberate use not as intended5.2%40
- Drug ineffectivethe medicine did not work as expected4.6%36
- Coughcough3.2%25
- Covid-19COVID-19 infection3.1%24
- Dry mouthdry mouth3%23
- Chronic obstructive pulmonary diseaseCOPD, a long-term lung disease2.7%21
- Pneumonialung infection2.6%20
- Deaththe patient died; cause not stated by this term2.2%17
- Dysphoniaa hoarse voice1.8%14
- Intentional overdosea deliberate overdose1.8%14
- Oropharyngeal painsore throat1.7%13
- Bronchitischest infection1.3%10
- Dizzinesslight-headedness or unsteadiness1.3%10
- Incorrect route of drug administrationthe medicine was given by the wrong route1.3%10
- Intentional product misusedeliberate use not as intended1.3%10
- Chest painchest pain1.2%9
- Fatiguetiredness1.2%9
- Constipationconstipation1%8
- Lung neoplasm malignantlung cancer1%8
- Product delivery mechanism issue1%8
- Atrial fibrillationan irregular heart rhythm0.9%7
- Device delivery system issuea problem with the delivery system0.9%7
- Device issuea problem with the device0.9%7
Top 30 of 124 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Chronic obstructive pulmonary disease | 392 | 50.5% |
| Asthma | 47 | 6.1% |
| Emphysema | 20 | 2.6% |
| Dyspnoea | 6 | 0.8% |
| Lung disorder | 6 | 0.8% |
| Bronchitis chronic | 3 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 776 reports.
In context
| Measure | Spiriva Handihaler | All reports |
|---|---|---|
| Reports as suspect product | 776 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 18.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 31 | 91 |
| Hospitalisation recorded, per 1,000 reports | 82 | 213 |
| Consumer-filed share | 91.2% | 45.8% |
| Top term, share of reports | Incorrect route of product administration 25.1% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Spiriva Handihaler reports
How many adverse event reports has FDA received for Spiriva Handihaler?
776 reports list Spiriva Handihaler as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 241 list it only as a concomitant medication.
What reactions are recorded in Spiriva Handihaler reports?
incorrect route of product administration (25.1%), product physical issue (14%), dyspnoea (12.5%), product use issue (12.2%) and product quality issue (9.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Spiriva Handihaler was responsible.
How serious are the reports?
18.3% are marked serious by the reporter. Among the outcomes recorded, 3.1% of reports include death and 8.2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (91.2%), pharmacist (3.2%) and other health professional (2.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Spiriva Handihaler rising?
0 reports in the 12 months to June 2026, against 10 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Spiriva Handihaler was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Spiriva Handihaler?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Spiriva Handihaler as a suspect or interacting product; reports listing it only as a concomitant medication (241) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.